Earnings per share

12 Months Ended

Jun. 30, 2019

Note 33. Earnings per share


	2019 A$’000			2018 A$’000			2017 A$’000

Loss after income tax attributable to the owners of Kazia Therapeutics Limited		(10,270	)		(6,039	)		(10,670	)

Loss after income tax attributable to the owners of Kazia Therapeutics Limited		(10,270	)		(6,039	)		(10,670	)


	Number			Number			Number

Weighted average number of ordinary shares used in calculating basic earnings per share		57,503,555			48,376,525			467,833,849

Weighted average number of ordinary shares used in calculating Diluted earnings per share		57,503,555			48,376,525			467,833,849


	Cents			Cents			Cents
Basic earnings per share		(17.86	)		(12.48	)		(2.28	)
Diluted earnings per share		(17.86	)		(12.48	)		(2.28	)

1,865,000 unlisted convertible notes with a face value of A$464,000, 5,048,266 unlisted options and 3,148,400 listed options have been excluded from the above calculations as they were antidilutive.